Comparative Pharmacology
Head-to-head clinical analysis: DORYX MPC versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX MPC versus OXYTETRACYCLINE HYDROCHLORIDE.
DORYX MPC vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic